KR101029705B1 - 신규 펩타이드 및 그 용도 - Google Patents

신규 펩타이드 및 그 용도 Download PDF

Info

Publication number
KR101029705B1
KR101029705B1 KR1020100062467A KR20100062467A KR101029705B1 KR 101029705 B1 KR101029705 B1 KR 101029705B1 KR 1020100062467 A KR1020100062467 A KR 1020100062467A KR 20100062467 A KR20100062467 A KR 20100062467A KR 101029705 B1 KR101029705 B1 KR 101029705B1
Authority
KR
South Korea
Prior art keywords
peptide
cartilage
pharmaceutically acceptable
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020100062467A
Other languages
English (en)
Korean (ko)
Inventor
김해진
이제욱
권영준
문은정
Original Assignee
(주)엔솔테크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)엔솔테크 filed Critical (주)엔솔테크
Priority to KR1020100062467A priority Critical patent/KR101029705B1/ko
Application granted granted Critical
Publication of KR101029705B1 publication Critical patent/KR101029705B1/ko
Priority to MX2012015000A priority patent/MX2012015000A/es
Priority to SG2012088381A priority patent/SG186120A1/en
Priority to ES11801075.0T priority patent/ES2606778T3/es
Priority to BR112012031587-0A priority patent/BR112012031587B1/pt
Priority to CA2801010A priority patent/CA2801010C/en
Priority to EP11801075.0A priority patent/EP2588491B1/en
Priority to AU2011272137A priority patent/AU2011272137B2/en
Priority to RU2013101051/04A priority patent/RU2525913C1/ru
Priority to PL11801075T priority patent/PL2588491T3/pl
Priority to CN201180004884.2A priority patent/CN102892776B/zh
Priority to PCT/KR2011/004541 priority patent/WO2012002668A2/en
Priority to JP2012544408A priority patent/JP5607176B2/ja
Priority to US13/701,465 priority patent/US8772241B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020100062467A 2010-06-30 2010-06-30 신규 펩타이드 및 그 용도 Active KR101029705B1 (ko)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020100062467A KR101029705B1 (ko) 2010-06-30 2010-06-30 신규 펩타이드 및 그 용도
US13/701,465 US8772241B2 (en) 2010-06-30 2011-06-22 Peptide and use thereof
CA2801010A CA2801010C (en) 2010-06-30 2011-06-22 Peptide and use thereof for treatment of cartilage damage and arthritis
RU2013101051/04A RU2525913C1 (ru) 2010-06-30 2011-06-22 Новый пептид и его применение
ES11801075.0T ES2606778T3 (es) 2010-06-30 2011-06-22 Péptido novedoso y uso del mismo
BR112012031587-0A BR112012031587B1 (pt) 2010-06-30 2011-06-22 Composição compreendendo um peptídeo e pelo menos um outro componente farmaceuticamente aceitável para o tratamento ou prevenção de dano de cartilagem e artrite
MX2012015000A MX2012015000A (es) 2010-06-30 2011-06-22 Nuevo peptido y uso del mismo.
EP11801075.0A EP2588491B1 (en) 2010-06-30 2011-06-22 Novel peptide and use thereof
AU2011272137A AU2011272137B2 (en) 2010-06-30 2011-06-22 Novel peptide and use thereof
SG2012088381A SG186120A1 (en) 2010-06-30 2011-06-22 Novel peptide and use thereof
PL11801075T PL2588491T3 (pl) 2010-06-30 2011-06-22 Nowy peptyd i jego zastosowanie
CN201180004884.2A CN102892776B (zh) 2010-06-30 2011-06-22 新型肽及其用途
PCT/KR2011/004541 WO2012002668A2 (en) 2010-06-30 2011-06-22 Novel peptide and use thereof
JP2012544408A JP5607176B2 (ja) 2010-06-30 2011-06-22 新規ペプチドおよびその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100062467A KR101029705B1 (ko) 2010-06-30 2010-06-30 신규 펩타이드 및 그 용도

Publications (1)

Publication Number Publication Date
KR101029705B1 true KR101029705B1 (ko) 2011-04-18

Family

ID=44050220

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100062467A Active KR101029705B1 (ko) 2010-06-30 2010-06-30 신규 펩타이드 및 그 용도

Country Status (14)

Country Link
US (1) US8772241B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588491B1 (cg-RX-API-DMAC7.html)
JP (1) JP5607176B2 (cg-RX-API-DMAC7.html)
KR (1) KR101029705B1 (cg-RX-API-DMAC7.html)
CN (1) CN102892776B (cg-RX-API-DMAC7.html)
AU (1) AU2011272137B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012031587B1 (cg-RX-API-DMAC7.html)
CA (1) CA2801010C (cg-RX-API-DMAC7.html)
ES (1) ES2606778T3 (cg-RX-API-DMAC7.html)
MX (1) MX2012015000A (cg-RX-API-DMAC7.html)
PL (1) PL2588491T3 (cg-RX-API-DMAC7.html)
RU (1) RU2525913C1 (cg-RX-API-DMAC7.html)
SG (1) SG186120A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012002668A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019054809A3 (ko) * 2017-09-15 2019-06-06 주식회사 바이오펩 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도
US20200276260A1 (en) 2017-09-15 2020-09-03 Kine Sciences Co., Ltd. Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
WO2024122716A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2024122727A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104886564B (zh) * 2015-05-12 2017-05-17 浙江海洋学院 一种路氏双髻鲨软骨血管生成抑制因子的用途
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
WO2017155234A1 (ko) * 2016-03-09 2017-09-14 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
US10913771B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
US10913772B2 (en) 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
KR101897122B1 (ko) * 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
EP3428178A4 (en) * 2016-03-09 2019-09-04 Bio Pep Co., Ltd. PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES AND USE THEREOF
EP3489253B1 (en) * 2016-07-20 2023-03-01 Ensol Biosciences Inc. Novel peptide and use thereof
CN107670021B (zh) * 2016-08-02 2020-09-18 富比积生物科技股份有限公司 五胜肽kttks在治疗退化性关节炎中的用途
KR101995768B1 (ko) * 2019-03-13 2019-07-03 (주)엔솔바이오사이언스 신규 펩타이드 및 그 용도
KR20230167231A (ko) 2022-05-31 2023-12-08 주식회사 엔솔바이오사이언스 염형태 변형 펩타이드의 제조방법 및 그를 이용하여 제조된 펩타이드
KR20230167253A (ko) 2022-05-31 2023-12-08 주식회사 엔솔바이오사이언스 펩타이드 함유 액상제제 및 그 제조방법
KR102971166B1 (ko) * 2022-12-09 2026-06-01 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2025089468A1 (ko) 2023-10-27 2025-05-01 주식회사 엔솔바이오사이언스 펩타이드 함유 액상제제 및 그 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955343A (en) * 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US6638912B2 (en) * 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US6716811B1 (en) * 2000-07-20 2004-04-06 Affymax, Inc. Compounds having affinity for the granulocyte-colony stimulating factor receptor (G-CSFR) and associated uses
WO2002062969A2 (en) * 2001-02-06 2002-08-15 Massachusetts Institute Of Technology Cellular reprogramming in peptide hydrogel and uses thereof
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US8039258B2 (en) * 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
CN101611051A (zh) * 2005-02-16 2009-12-23 加州大学董事会 治疗或预防骨疾病的药物组合物
US7888462B2 (en) 2007-01-22 2011-02-15 Acologix, Inc. Peptide composition and a method of promoting cartilage formation
CA2618163A1 (en) * 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochim Biophys Acta. 1992 Sep 24;1132(2):225-7.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019054809A3 (ko) * 2017-09-15 2019-06-06 주식회사 바이오펩 자가면역질환 및 골질환 치료제로서의 펩타이드의 용도
US20200276260A1 (en) 2017-09-15 2020-09-03 Kine Sciences Co., Ltd. Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
US11730788B2 (en) 2017-09-15 2023-08-22 Kine Sciences Co., Ltd. Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
WO2024122716A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2024122727A1 (ko) * 2022-12-09 2024-06-13 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
KR20240086939A (ko) * 2022-12-09 2024-06-19 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
KR102877150B1 (ko) 2022-12-09 2025-10-28 (주)케어젠 연골 재생용 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
JP2013513657A (ja) 2013-04-22
US8772241B2 (en) 2014-07-08
BR112012031587A2 (pt) 2017-12-05
CN102892776B (zh) 2014-07-16
EP2588491B1 (en) 2016-09-14
RU2525913C1 (ru) 2014-08-20
AU2011272137A1 (en) 2013-02-14
US20130109626A1 (en) 2013-05-02
RU2013101051A (ru) 2014-08-10
EP2588491A2 (en) 2013-05-08
SG186120A1 (en) 2013-01-30
CA2801010A1 (en) 2012-01-05
CA2801010C (en) 2015-10-13
EP2588491A4 (en) 2013-12-04
BR112012031587B1 (pt) 2021-07-13
ES2606778T3 (es) 2017-03-27
MX2012015000A (es) 2013-02-07
WO2012002668A3 (en) 2012-04-26
PL2588491T3 (pl) 2017-03-31
CN102892776A (zh) 2013-01-23
WO2012002668A2 (en) 2012-01-05
AU2011272137B2 (en) 2016-09-29
JP5607176B2 (ja) 2014-10-15

Similar Documents

Publication Publication Date Title
EP2588491B1 (en) Novel peptide and use thereof
KR102631542B1 (ko) 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
US20250345393A1 (en) Isoform nell-1 peptide
AU2026201137A1 (en) Compositions and methods for promoting islet viability and enhancing insulin secretion
CN110903381B (zh) 一种促进软骨再生的肽kai 11及其应用
KR101736280B1 (ko) 관절염 예방 또는 치료용 약학적 조성물
EA038283B1 (ru) Способ лечения или предупреждения остеоартрита
Di Nicola et al. Biological baseline of joint self-repair procedures
EP4631957A1 (en) Peptide for cartilage regeneration, and uses thereof
CN120418270A (zh) 用于软骨再生的肽及其用途
CN120435484A (zh) 用于软骨再生的肽及其用途
CN120418267A (zh) 用于软骨再生的肽及其用途
CN120380007A (zh) 用于软骨再生的肽及其用途
CN120435483A (zh) 用于软骨再生的肽及其用途
CN120418272A (zh) 用于软骨再生的肽及其用途
CN120418266A (zh) 用于软骨再生的肽及其用途
ES2605813A1 (es) Uso de osteostatina en la preparación de un medicamento para el tratamiento de artrosis

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20140411

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20160411

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20170411

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20180411

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20190410

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1, 2, 3, 6, Period Limitation Text : 572, Comment Text : 380-001

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1, 2, 3, 6, Period Limitation Text : 572, Comment Text : 380-001

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 15